Icon

KISQALI FEMARA CO-PACK (COPACKAGED) (nda209935)- (2.5MG;EQ 200MG BASE)

LETROZOLE; RIBOCICLIB SUCCINATE NOVARTIS
2.5MG;EQ 200MG BASE
Yes No
2036-Apr-14 2022-Mar-13
None None
None No
KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
0 1 0
Total Other Developers None
Drugs with Suitability No
2.5MG;EQ 200MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.